Skip to content

Enhancing Kidney Donation Through Live Organ Video Educated Donors (LOVED) Study Phase

Enhancing Kidney Donation Through Live Organ Video Educated Donors (LOVED) Study Phase

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03599102
Acronym
LOVED
Enrollment
54
Registered
2018-07-26
Start date
2016-08-31
Completion date
2018-02-28
Last updated
2021-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Brief summary

LOVED stands for the Living Organ Video Educated Donors (LOVED) program. It is a culturally tailored program for African Americans to reduce the disparity of low rates of living kidney donation. It is a mobile health delivered platform that does not require transplant center visits, thus increasing the reach of the program compared to center-based program to enhance living kidney donation. The purpose of LOVED is to give education and encouragement to those who need a kidney transplant and teach about the process of living donation to be better educated when approaching others about donating a kidney. The ultimate goal of the program is to increase the number of living kidney donor transplants, especially among African Americans in South Carolina. The program was created to educate those in need of a kidney about the donor process, to dispel myths about living donation, discuss who can be asked to donate and develop and practice skills to start asking others for a living kidney donation. The program is designed to be completed using a tablet computer and is made up of weekly video education clips, resources, short quizzes to reinforce the learning points and weekly video chat sessions with others who need a kidney led by a navigator who was once a living donor kidney recipient. The video clips are made up of stories and brief educational messages from transplant center staff, physicians, former donors and recipients. The video chat sessions were designed to solve and address individual issues for those enrolled in the program and to give a sense of community as they continue on their journey to find a kidney. This randomized control trial uses groups of 6-9 participants in each LOVED group that lasts 8-weeks each. A total of 60 participants will be recruited with 30 assigned to LOVED and 30 assigned to a standard care groups. This program is funded by a grant from the National Institute of Health and was developed at the Medical University of South Carolina.

Interventions

BEHAVIORALLOVED Intervention

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 18-65 years old * African American * Legally competent * Able to read and speak in English * Able to use tablet computers (after instruction) * Able to use cell phone * 5 years or less on the kidney waitlist with active status including pre-emptive and ESRD patients on dialysis * 10 years or less on dialysis

Exclusion criteria

* Patients who have currently identified PDs moving through the evaluation stage

Design outcomes

Primary

MeasureTime frameDescription
Change in self-efficacy to ask others to be a living donorChange between 0 and 8 weeks and change between 0 and 6 monthsWillingness to Discuss LDKT Scale (i.e., measuring self-efficacy (SE)) (1 item each for family, friends, and strangers7 pt. Likert scale) 1-7 range with higher values representing higher SE to approach others about living donation
Change in attitudes on living donationChange between 0 and 8 weeks and change between 0 and 6 monthsLDKT Concerns Scale (i.e., measuring attitudes) (21 T/F with one point for each statement suggestive of more worry); 0-21 range with higher results representing more concerns about LDKT.
Change in knowledge about living donationChange between 0 and 8 weeks and change between 0 and 6 monthsScore measures for self-efficacy, knowledge and attitudes to approach others to be a living donor -LDKT Knowledge Scale (knowledge) (15 item T/F); each correct response adds 1 point. 0-15 range with higher numbers represent higher knowledge.
Participant adherence to study protocolsAssessed at 8 weeksTolerability as defined by % retention to study (% of participants who self-remove from the study) Fidelity as defined by %adherence to chat sessions and completion %of video modules.

Secondary

MeasureTime frameDescription
Completing living donor kidney transplantation8 weeks, 6 months% who identify potential donors, % elected to be screened and, % completing Living donor kidney transplantation (from clinical records compared between groups)

Other

MeasureTime frameDescription
Assessment of making autonomous decisions8 weeksShared Decision Making Questionnaire (SDM-Q-9), a 6 question 4-item Likert scale (1=strongly agree to 4=strongly disagree) involved decision making between the participant and Loved Navigator. Questions were averaged (range 1-4). Lower scores represent better ability to make decisions.
Assessment of communication satisfaction8 weeksAssess feelings of how the communication was administrated during the study. Communication Effectiveness Questionnaire, a 9 question 5-item Likert scale between the participant and the navigator, research staff and renal transplant team. Questions were averaged (range 1-4). Higher sum scores represent higher communication perceptions.
Assessment of cultural competency8 weeksAssess feelings of inclusion based on race during study process. Experiences of Discrimination, a 5 question, 4-tem Likert scale. Questions were averaged (range 1-4). Higher sum scores represent higher trust perceptions.
Assessment of feelings of trust8 weeksAssess if the participant feels distrust of study staff, and medical providers during after the trial. Abbreviated Trust Measure, 3 question, 4-item Likert scale between participant and navigator. Question scores were averaged where higher scores indicated more trust (range 1-4).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026